JP2020520963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520963A5 JP2020520963A5 JP2019564822A JP2019564822A JP2020520963A5 JP 2020520963 A5 JP2020520963 A5 JP 2020520963A5 JP 2019564822 A JP2019564822 A JP 2019564822A JP 2019564822 A JP2019564822 A JP 2019564822A JP 2020520963 A5 JP2020520963 A5 JP 2020520963A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administration
- hours
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 206010011971 Decreased interest Diseases 0.000 claims 1
- 206010012374 Depressed mood Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023009149A JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510481P | 2017-05-24 | 2017-05-24 | |
| US62/510,481 | 2017-05-24 | ||
| US15/933,673 | 2018-03-23 | ||
| US15/933,673 US20180338959A1 (en) | 2017-05-24 | 2018-03-23 | Treatment of depressive disorders |
| PCT/US2018/033848 WO2018217718A1 (en) | 2017-05-24 | 2018-05-22 | Treatment of depressive disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009149A Division JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520963A JP2020520963A (ja) | 2020-07-16 |
| JP2020520963A5 true JP2020520963A5 (https=) | 2021-07-26 |
Family
ID=64395877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564822A Pending JP2020520963A (ja) | 2017-05-24 | 2018-05-22 | 抑うつ障害の処置 |
| JP2023009149A Withdrawn JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009149A Withdrawn JP2023061957A (ja) | 2017-05-24 | 2023-01-25 | 抑うつ障害の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20180338959A1 (https=) |
| EP (2) | EP3939587A1 (https=) |
| JP (2) | JP2020520963A (https=) |
| KR (1) | KR20200018485A (https=) |
| CN (2) | CN115105499A (https=) |
| AU (1) | AU2018272819A1 (https=) |
| CA (1) | CA3064299A1 (https=) |
| IL (1) | IL270781A (https=) |
| MX (1) | MX393452B (https=) |
| WO (1) | WO2018217718A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| US10987303B2 (en) * | 2018-05-02 | 2021-04-27 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| AU2020223284A1 (en) | 2019-02-17 | 2021-09-16 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| KR102085938B1 (ko) * | 2019-11-04 | 2020-03-06 | 한국메탈실리콘 주식회사 | 실리콘 복합체 제조방법 |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| BRPI0410857A (pt) * | 2003-06-25 | 2006-07-04 | Lundbeck & Co As H | método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica |
| JP2007530604A (ja) | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| US10628156B2 (en) * | 2013-07-09 | 2020-04-21 | Texas Instruments Incorporated | Vector SIMD VLIW data path architecture |
| RS62007B1 (sr) * | 2014-06-06 | 2021-07-30 | Ovid Therapeutics Inc | Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma |
| EP4541420A3 (en) * | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| AU2020313930A1 (en) * | 2019-07-15 | 2022-02-03 | Ovid Therapeutics Inc. | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
-
2018
- 2018-03-23 US US15/933,673 patent/US20180338959A1/en not_active Abandoned
- 2018-05-22 EP EP21195602.4A patent/EP3939587A1/en not_active Withdrawn
- 2018-05-22 EP EP18805653.5A patent/EP3630065A4/en not_active Withdrawn
- 2018-05-22 WO PCT/US2018/033848 patent/WO2018217718A1/en not_active Ceased
- 2018-05-22 MX MX2019014024A patent/MX393452B/es unknown
- 2018-05-22 CN CN202210735249.1A patent/CN115105499A/zh active Pending
- 2018-05-22 CA CA3064299A patent/CA3064299A1/en active Pending
- 2018-05-22 AU AU2018272819A patent/AU2018272819A1/en not_active Abandoned
- 2018-05-22 JP JP2019564822A patent/JP2020520963A/ja active Pending
- 2018-05-22 CN CN201880048161.4A patent/CN110996910A/zh active Pending
- 2018-05-22 KR KR1020197038042A patent/KR20200018485A/ko not_active Ceased
- 2018-12-18 US US16/223,356 patent/US20190117633A1/en not_active Abandoned
-
2019
- 2019-11-20 IL IL270781A patent/IL270781A/en unknown
-
2020
- 2020-02-19 US US16/794,354 patent/US20200179351A1/en not_active Abandoned
-
2021
- 2021-08-18 US US17/405,525 patent/US20210379028A1/en not_active Abandoned
-
2023
- 2023-01-25 JP JP2023009149A patent/JP2023061957A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520963A5 (https=) | ||
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| JP2015518897A5 (https=) | ||
| JPWO2006035876A1 (ja) | 関節リウマチの予防及び／又は治療薬 | |
| JP2006503839A (ja) | 真菌感染の処置のためのポサコナゾールの使用 | |
| JP2020532531A5 (https=) | ||
| JP2020514282A5 (https=) | ||
| JP2013518124A5 (https=) | ||
| Zhang et al. | The safety and efficacy of intranasal dexmedetomidine during electrochemotherapy for facial vascular malformation: a double-blind, randomized clinical trial | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| CN109316480A (zh) | 组合als疗法 | |
| JP2016505050A5 (https=) | ||
| JP2008540405A5 (https=) | ||
| Chen et al. | Efficacy and Safety of Mepolizumab as an Add-on Therapy in Chinese Patients With Severe Eosinophilic Asthma: A Randomized, Double-Blind, Parallel Group Phase 3 Study | |
| Yeh et al. | Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels | |
| CN108685928A (zh) | 毛壳素在制备治疗肝纤维化药物中的应用 | |
| JP2017511307A5 (https=) | ||
| JP2015515971A5 (https=) | ||
| RU2019110755A (ru) | Сублингвальное или буккальное введение dim для лечения заболеваний кожи | |
| JP2003535133A5 (https=) | ||
| CN104687927A (zh) | 一种具有降压作用的保健药枕 | |
| US20240358726A1 (en) | Specific therapeutic medical marijuana doses for stress and pain | |
| Górecka | Short burst oxygen therapy is unhelpful? | |
| Lee et al. | Spiraea prunifolia var. simpliciflora downregulates inflammatory responses and oxidative stress in a mouse model of PPE/LPSinduced chronic obstructive pulmonary disease |